Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.

Chen J, Bearz A, Kim DW, Mamdani H, Bauman J, Chiari R, Ou SI, Solomon BJ, Soo RA, Felip E, Shaw AT, Thurm H, Clancy JS, Lee K, O'Gorman M, Tanski C, Pithavala YK

Open source

DOI: 10.1007/s40262-023-01309-4
Published: 2024 Feb
Container: Clinical pharmacokinetics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40262-023-01309-4,
  title = {Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.},
  author = {Chen J and Bearz A and Kim DW and Mamdani H and Bauman J and Chiari R and Ou SI and Solomon BJ and Soo RA and Felip E and Shaw AT and Thurm H and Clancy JS and Lee K and O'Gorman M and Tanski C and Pithavala YK},
  year = {2024},
  journal = {Clinical pharmacokinetics},
  doi = {10.1007/s40262-023-01309-4},
  url = {https://doi.org/10.1007/s40262-023-01309-4}
}

RIS

TY  - JOUR
TI  - Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
AU  - Chen J
AU  - Bearz A
AU  - Kim DW
AU  - Mamdani H
AU  - Bauman J
AU  - Chiari R
AU  - Ou SI
AU  - Solomon BJ
AU  - Soo RA
AU  - Felip E
AU  - Shaw AT
AU  - Thurm H
AU  - Clancy JS
AU  - Lee K
AU  - O'Gorman M
AU  - Tanski C
AU  - Pithavala YK
PY  - 2024
JO  - Clinical pharmacokinetics
DO  - 10.1007/s40262-023-01309-4
UR  - https://doi.org/10.1007/s40262-023-01309-4
ER  -

APA

J, C., A, B., DW, K., H, M., J, B., R, C., SI, O., BJ, S., RA, S., E, F., AT, S., H, T., JS, C., K, L., M, O., C, T., & YK, P. (2024). Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.. Clinical pharmacokinetics. https://doi.org/10.1007/s40262-023-01309-4

Source records

pubmed · retrieved 2026-09-25T23:41:36.499Z